JP2015506980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506980A5 JP2015506980A5 JP2014556658A JP2014556658A JP2015506980A5 JP 2015506980 A5 JP2015506980 A5 JP 2015506980A5 JP 2014556658 A JP2014556658 A JP 2014556658A JP 2014556658 A JP2014556658 A JP 2014556658A JP 2015506980 A5 JP2015506980 A5 JP 2015506980A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formulation according
- viloxazine
- component
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 238000009472 formulation Methods 0.000 claims 38
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 13
- 229960001255 viloxazine Drugs 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 6
- 239000012730 sustained-release form Substances 0.000 claims 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 5
- 230000003111 delayed effect Effects 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000002433 hydrophilic molecules Chemical class 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- HJOCKFVCMLCPTP-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)methyl]morpholine;hydron;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCC1OCCNC1 HJOCKFVCMLCPTP-UHFFFAOYSA-N 0.000 claims 1
- SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 claims 1
- 206010000125 Abnormal dreams Diseases 0.000 claims 1
- 241000220479 Acacia Species 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 229920002494 Zein Polymers 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- XPNLOZNCOBKRNJ-UHFFFAOYSA-N ethyl prop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C=C.COC(=O)C(C)=C XPNLOZNCOBKRNJ-UHFFFAOYSA-N 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 125000005908 glyceryl ester group Chemical group 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 229960005014 viloxazine hydrochloride Drugs 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 239000005019 zein Substances 0.000 claims 1
- 229940093612 zein Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596458P | 2012-02-08 | 2012-02-08 | |
| US61/596,458 | 2012-02-08 | ||
| PCT/US2013/025121 WO2013119794A1 (en) | 2012-02-08 | 2013-02-07 | Modified release formulations of viloxazine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018018946A Division JP6510093B2 (ja) | 2012-02-08 | 2018-02-06 | ビロキサジンの緩和放出製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506980A JP2015506980A (ja) | 2015-03-05 |
| JP2015506980A5 true JP2015506980A5 (enExample) | 2016-01-21 |
| JP6290100B2 JP6290100B2 (ja) | 2018-03-07 |
Family
ID=47741312
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556658A Active JP6290100B2 (ja) | 2012-02-08 | 2013-02-07 | ビロキサジンの緩和放出製剤 |
| JP2018018946A Active JP6510093B2 (ja) | 2012-02-08 | 2018-02-06 | ビロキサジンの緩和放出製剤 |
| JP2019066455A Active JP6832973B2 (ja) | 2012-02-08 | 2019-03-29 | ビロキサジンの緩和放出製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018018946A Active JP6510093B2 (ja) | 2012-02-08 | 2018-02-06 | ビロキサジンの緩和放出製剤 |
| JP2019066455A Active JP6832973B2 (ja) | 2012-02-08 | 2019-03-29 | ビロキサジンの緩和放出製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US9358204B2 (enExample) |
| EP (2) | EP2812074B1 (enExample) |
| JP (3) | JP6290100B2 (enExample) |
| AU (4) | AU2013217013B2 (enExample) |
| CA (1) | CA2864088C (enExample) |
| ES (1) | ES2950875T3 (enExample) |
| MX (2) | MX356727B (enExample) |
| WO (1) | WO2013119794A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2735934C (en) | 2008-09-05 | 2014-01-07 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| US20240041893A1 (en) | 2023-10-03 | 2024-02-08 | Innovate Therapeutics Llc | An Extended-Release Pharmaceutical Formulation of Viloxazine And Process For Preparation Thereof |
| WO2025135797A1 (ko) * | 2023-12-18 | 2025-06-26 | 주식회사 아스트로젠 | (s)-빌록사진 또는 이의 염의 개선된 제조 방법 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1138405A (en) | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
| FR2453639A1 (fr) * | 1979-04-09 | 1980-11-07 | Sanofi Sa | Composition medicamenteuse a liberation programmee immediate-retard a base de naftidrofuryl |
| US4260606A (en) | 1979-07-19 | 1981-04-07 | A. H. Robins Company, Inc. | 3-Methyleneazetidine derivatives |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| DE19830201A1 (de) | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| WO2000006162A1 (de) | 1998-07-27 | 2000-02-10 | Boehringer Ingelheim Pharma Kg | Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum |
| MXPA03006003A (es) | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| WO2002087549A1 (fr) * | 2001-04-25 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee du type a unites multiples |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| WO2004073695A1 (en) * | 2003-02-21 | 2004-09-02 | Lek Pharmaceuticals D.D | Therapeutic system comprising amoxicillin and clavulanic acid |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| US7119031B2 (en) * | 2004-06-28 | 2006-10-10 | Micron Technology, Inc. | Methods of forming patterned photoresist layers over semiconductor substrates |
| DE102004035938A1 (de) * | 2004-07-23 | 2006-02-16 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil |
| US7288347B2 (en) | 2004-08-31 | 2007-10-30 | Xerox Corporation | Method of applying spot varnish to xerographic image and emulsion aggregation toners for use therein |
| MX2007012947A (es) * | 2005-04-18 | 2008-04-09 | Rubicon Res Pvt Ltd | Composiciones biomejoradas. |
| US9161918B2 (en) * | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| WO2007026219A2 (en) | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| EP2457563B1 (en) * | 2006-05-09 | 2017-03-22 | Mallinckrodt LLC | Zero-order modified release solid dosage forms |
| EP1973528B1 (en) * | 2006-11-17 | 2012-11-07 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
| WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM |
| CA2706651A1 (en) * | 2007-12-04 | 2009-06-11 | Merck Sharp & Dohme Corp. | Tryptamine sulfonamides as 5-ht6 antagonists |
| CA2735934C (en) | 2008-09-05 | 2014-01-07 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| MX2011011579A (es) * | 2009-04-30 | 2012-01-27 | Supernus Pharmaceuticals Inc | Metodo de tratamiento contra la depresion. |
| WO2011008298A2 (en) * | 2009-07-16 | 2011-01-20 | Nectid, Inc. | Novel axomadol dosage forms |
| CN102548544B (zh) * | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
| AU2013217013B2 (en) * | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
-
2013
- 2013-02-07 AU AU2013217013A patent/AU2013217013B2/en active Active
- 2013-02-07 JP JP2014556658A patent/JP6290100B2/ja active Active
- 2013-02-07 CA CA2864088A patent/CA2864088C/en active Active
- 2013-02-07 US US13/761,757 patent/US9358204B2/en active Active
- 2013-02-07 EP EP13705348.4A patent/EP2812074B1/en active Active
- 2013-02-07 WO PCT/US2013/025121 patent/WO2013119794A1/en not_active Ceased
- 2013-02-07 ES ES13705348T patent/ES2950875T3/es active Active
- 2013-02-07 MX MX2014009528A patent/MX356727B/es active IP Right Grant
- 2013-02-07 EP EP23172156.4A patent/EP4233915A3/en active Pending
-
2014
- 2014-08-07 MX MX2023003000A patent/MX2023003000A/es unknown
-
2016
- 2016-05-18 US US15/157,549 patent/US9603853B2/en active Active
- 2016-06-03 US US15/172,955 patent/US9662338B2/en active Active
-
2017
- 2017-05-25 US US15/605,108 patent/US10265319B2/en active Active
- 2017-07-20 AU AU2017206245A patent/AU2017206245B2/en active Active
-
2018
- 2018-02-06 JP JP2018018946A patent/JP6510093B2/ja active Active
-
2019
- 2019-03-08 US US16/297,194 patent/US20190201407A1/en active Pending
- 2019-03-29 JP JP2019066455A patent/JP6832973B2/ja active Active
- 2019-08-16 AU AU2019216707A patent/AU2019216707B2/en active Active
-
2020
- 2020-09-18 AU AU2020233746A patent/AU2020233746B2/en active Active
-
2023
- 2023-08-10 US US18/232,716 patent/US20230381191A1/en not_active Abandoned
-
2025
- 2025-03-28 US US19/093,755 patent/US20250222004A1/en active Pending
- 2025-04-07 US US19/171,852 patent/US20250228859A1/en active Pending
- 2025-08-21 US US19/306,464 patent/US20250367208A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10987324B2 (en) | Methods and compositions for the treatment of seizure-related disorders | |
| JP2020023518A5 (enExample) | ||
| AU2012230733B2 (en) | Methods and compositions for treatment of attention deficit disorder | |
| JP2017128614A5 (enExample) | ||
| US20100255067A1 (en) | Controlled Release Pharmaceutical Compositions of Pregabalin | |
| ES2623176T3 (es) | Composición farmacéutica de memantina | |
| JP2015506980A5 (enExample) | ||
| US12370144B2 (en) | Centanafadine pharmaceutical formulations, and methods of making and using same | |
| CN114404393B (zh) | 一种拉考沙胺药物组合物及其药物制剂 | |
| JP6832973B2 (ja) | ビロキサジンの緩和放出製剤 | |
| EA031255B1 (ru) | Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения | |
| JP2016523250A5 (enExample) | ||
| WO2014143380A1 (en) | Extended-release topiramate capsules | |
| CA3021071A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2013523757A5 (enExample) | ||
| EP2994112A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof | |
| JP2008535922A (ja) | 細菌感染を治療するためのセファロスポリンを含む放出制御組成物 | |
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| JP2017019880A5 (enExample) | ||
| RU2015128915A (ru) | Составы лоразепама с замедленным высвобождением | |
| ES2394888B1 (es) | Forma farmacéutica de liberación modificada de dexketoprofeno e inhibidor de la bomba de protones y uso de la misma. |